GW Pharmaceuticals PLC (GWPH) Stock Rating Upgraded by Vetr Inc.
GW Pharmaceuticals PLC (NASDAQ:GWPH) was upgraded by investment analysts at Vetr from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday. The brokerage currently has a $141.40 price target on the biopharmaceutical company’s stock. Vetr‘s price target points to a potential upside of 12.93% from the stock’s previous close.
A number of other research analysts also recently weighed in on GWPH. Piper Jaffray Cos. restated a “buy” rating and issued a $147.00 price target on shares of GW Pharmaceuticals PLC in a research note on Sunday, June 26th. Cowen and Company reaffirmed a “buy” rating and issued a $135.00 price objective on shares of GW Pharmaceuticals PLC in a research report on Monday, June 27th. Zacks Investment Research raised GW Pharmaceuticals PLC from a “hold” rating to a “strong-buy” rating and set a $108.00 price objective for the company in a research report on Tuesday, July 5th. Leerink Swann reaffirmed an “outperform” rating and issued a $130.00 price objective on shares of GW Pharmaceuticals PLC in a research report on Wednesday, June 29th. Finally, Goldman Sachs Group Inc. cut their price objective on GW Pharmaceuticals PLC from $135.00 to $105.00 in a research report on Tuesday, June 28th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $143.40.
Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) traded down 1.31% during mid-day trading on Tuesday, reaching $125.21. The company’s stock had a trading volume of 359,535 shares. GW Pharmaceuticals PLC has a 52-week low of $35.83 and a 52-week high of $137.88. The firm’s market cap is $2.74 billion. The firm has a 50 day moving average price of $113.58 and a 200 day moving average price of $93.44.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/19/gw-pharmaceuticals-plc-gwph-stock-rating-upgraded-by-vetr-inc.html
GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.21) by $1.15. The firm earned $3.10 million during the quarter, compared to the consensus estimate of $3.63 million. GW Pharmaceuticals PLC had a negative return on equity of 26.26% and a negative net margin of 409.40%. The business’s revenue was down 73.3% compared to the same quarter last year. During the same period last year, the company earned ($0.09) earnings per share. On average, equities analysts predict that GW Pharmaceuticals PLC will post ($4.52) EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the stock. DekaBank Deutsche Girozentrale boosted its position in shares of GW Pharmaceuticals PLC by 12.2% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,340 shares of the biopharmaceutical company’s stock valued at $684,000 after buying an additional 800 shares in the last quarter. Jennison Associates LLC bought a new position in shares of GW Pharmaceuticals PLC during the second quarter valued at $7,131,000. Tocqueville Asset Management L.P. boosted its position in shares of GW Pharmaceuticals PLC by 7.1% in the second quarter. Tocqueville Asset Management L.P. now owns 27,900 shares of the biopharmaceutical company’s stock valued at $2,555,000 after buying an additional 1,850 shares in the last quarter. CAM Group Holding A S bought a new position in shares of GW Pharmaceuticals PLC during the second quarter valued at $1,053,000. Finally, Candriam Luxembourg S.C.A. bought a new position in shares of GW Pharmaceuticals PLC during the second quarter valued at $1,465,000. 68.50% of the stock is owned by hedge funds and other institutional investors.
GW Pharmaceuticals PLC Company Profile
GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.